INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression, and exhibits anticancer activity in ccne1-amplified cancers and cdk4/6i-resistant intraductal breast cancer models.
Molecular Weight:
427.48
Purity:
99.88%
CAS Number:
[2745060-92-6]
Formula:
C19H21N7O3S
Target:
Early 2 Factor (E2F)|||CDK
T86723
T86723
* VAT and and shipping costs not included. Errors and price changes excepted
